Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0VUGAK
ADC Name	Alpha-CD30-8
Synonyms	Alpha-CD30-8 Tub(OEt) Click to Show/Hide
Drug Status	Investigative
Indication	In total 2 Indication(s) Anaplastic large cell lymphoma [ICD11:2A90] Investigative Hodgkin lymphoma [ICD11:2B30] Investigative
Drug-to-Antibody Ratio	8
	3D MOL	2D MOL
Antibody Name	Anti-CD30 mAb		Antibody Info
Antigen Name	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)		Antigen Info
Payload Name	Tubulysin 8		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Glucuronide quaternary ammonium linker 8		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 97.1	%	L540cy cells	Hodgkin's disease
Tumor Growth Inhibition value (TGI)	≈ 99.2	%	DEL/BVR cells	Anaplastic large cell lymphoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.10% (Day 28)	Positive CD30 expression (CD30+++/++)
Method Description	Alpha-CD30-8 (0.3 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of CD30+, MDR-L540cy HL cells with CD30 expression with high expression.
In Vivo Model	L540cy CDX model
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.20% (Day 16)	Positive CD30 expression (CD30+++/++)
Method Description	Alpha-CD30-8 (1 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of CD30+, MDR+ DEL/BVR ALCL cells with CD30 expression with high expression.
In Vivo Model	DEL/BVR CDX model
In Vitro Model	Anaplastic large cell lymphoma	DEL/BVR cells		CVCL_1170

References

Ref 1	Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR(+) and Heterogeneous Tumor Models. Mol Cancer Ther. 2018 Aug;17(8):1752-1760. doi: 10.1158/1535-7163.MCT-18-0073. Epub 2018 Jun 4.